News

• November 22, 2021

  Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference >

  BALA CYNWYD, Pa. , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at

• November 15, 2021

  Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference >

  BALA CYNWYD, Pa. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the

• November 12, 2021

  Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results >

  BALA CYNWYD, Pa. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financial

• September 16, 2021

  Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event >

  BALA CYNWYD, Pa. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the

• September 2, 2021

  Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference >

  BALA CYNWYD, Pa. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• August 19, 2021

  Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress >

  BALA CYNWYD, Pa. , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of

• August 12, 2021

  Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results >

  - Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich’s ataxia (FA) - Subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in buccal cells of FA patients that were at or in excess of

• July 8, 2021

  Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 >

  BALA CYNWYD, Pa. , July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• June 11, 2021

  Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference >

  BALA CYNWYD, Pa. , June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• May 25, 2021

  Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing >

  BALA CYNWYD, Pa. , May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the United States Food and Drug

• May 21, 2021

  Larimar Therapeutics Announces $95 Million Private Placement Financing >

  BALA CYNWYD, Pa. , May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that it has executed a securities purchase

• May 20, 2021

  Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia >

  BALA CYNWYD, Pa. , May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the European Medicines Agency (EMA)

• May 11, 2021

  Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia >

  Data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo in all evaluated tissues Data show that frataxin levels achieved in peripheral tissues (buccal

• May 10, 2021

  Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results >

  - Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021 - Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa.

• March 4, 2021

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results >

  Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich's   ataxia (FA) patients Placebo-controlled Phase 1 trials in FA patients remain on track for topline data

• February 18, 2021

  Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference >

  BALA CYNWYD, Pa. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• December 15, 2020

  Larimar Therapeutics Added to NASDAQ Biotechnology Index >

  BALA CYNWYD, Pa. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index

• December 8, 2020

  Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update >

  - Preliminary data   suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo - controlled single and multiple   ascending dose clinical trials in Q2 2021 BALA CYNWYD, Pa. , Dec.

• November 13, 2020

  Larimar Therapeutics to Participate in Upcoming Investor Conferences >

  BALA CYNWYD, Pa. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will

• November 10, 2020

  Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results >

  Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia   on track for topline data in 1H   2021 Received orphan drug d esignation for CTI-1601 from the European Commission Cash, cash equivalents, and marketable securities of $102 . 3 million as of September 30, 2020 BALA CYNWYD,

• October 13, 2020

  Larimar Therapeutics Announces Formation of Scientific Advisory Board >

  BALA CYNWYD, Pa. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the formation of its Scientific Advisory Board (SAB).

• September 21, 2020

  Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit >

  BALA CYNWYD, Pa. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will virtually

• September 10, 2020

  Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference >

  BALA CYNWYD, Pa. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will participate in

• August 11, 2020

  Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results >

  Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar Therapeutics Phase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after delay due to COVID-19 related restrictions $80 million private placement financing completed with

• August 4, 2020

  Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference >

  BALA CYNWYD, Pa. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will present at the

• July 28, 2020

  Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia >

  BALA CYNWYD, Pa. , July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP)

• July 20, 2020

  Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia >

  BALA CYNWYD, Pa. , July 20, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that patients have been dosed in the third cohort of a Phase 1 clinical trial to evaluate

• May 29, 2020

  Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference >

  BALA CYNWYD, Pa. , May 29, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will present at the

• May 29, 2020

  Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics >

  - Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chief Financial Officer

---

View all News >